Summary.-Concentrations of 5-fluorouracil (FU) were measured in the plasma of patients receiving i.v. infusions of the drug for 5 days as treatment for adenocarcinoma of the gastrointestinal tract. Concentrations of FU varied widely in many patients. Concentration of drug x time of infusion (C x t values) were calculated.
THE RESPONSE of adenocarcinoma of the gastrointestinal tract to treatment with FU is less when the drug is given orally than i.v. . Also, the various regimens used for i.v. treatment produce different response rates (Ansfield et al., 1977) . Of these regimens, continuous infusion of drug for 5 days is the least toxic (Seifert et al., 1975) and, when combined with other drugs, gives good clinical responses (Woolley et al., 1976) . Some data are available on the plasma concentrations of FU after i.v. injection or oral administration (Cohen et al., 1974) , but only one other published study (Clarkson et al., 1964) besides our preliminary report gives data on plasma concentrations of drug during continuous i.v. infusion. These concentrations varied widely in the same patient during infusion, and the values of drug concentration x time varied widely between different patients. The present study was carried out to determine whether these drug concentrations related to tumour response and whether the administration of methyl CCNU on Day 1 of the infusion altered the plasma concentrations of FU.
MATERIALS AND METHODS
Selection ofpatients and treatment schedule.-Patients with measurable metastatic adenocarcinoma of the gastrointestinal tract who had not received F U or methyl CCNTU previously were treated by i.v. infusion of FU, 1-2 g/m2/day (not > 2 g) in 1 1 of 5% dextrose for 5 days. Infusion was either by gravity or with a Holter pump, on a nonrandom basis. Infusions were routinely supervised in a general medical ward. Some patients received methyl CCNU 150 mg/M2 by mouth on Day 1. Treatments were repeated at intervals of 6 weeks, unless severe drug toxicity or progression of disease occurred. Plasma levels of FU were determined during one or more of these courses.
Evaluation of toxicity and tumour response. -Stomatitis was graded as 1 if present but not affecting food intake, 2 if preventing intake of solid but not soft and liquid food, and 3 if preventing intake of anything by mouth. Haematological toxicity was not evaluated, as the patients were discharged from hospital at the time a fall in white cells and platelets would have occurred. Moreover, this form of toxicity is infrequent and asymptomatic when FU is given by continuous infusion at the dosage used (Seifert et al., 1975) .
A complete response was defined as the disappearance of all disease; partial response was the objective response as described by Seifert et al. (1975) Table I . For the other patients, blood samples were removed at daily intervals. The blood removed by venepuncture was collected in EDTA and the plasma removed and frozen. Batches of plasma were thawed and extracted as described and the FU deterImined by a massspectrometric method, previously reported. The standard error of our method with repeated analyses on the same sample was ± 4% and the sensitivity 5 ng/ml (Hillcoat et al., 1976) .
RESULTS
Plasma concentrations of 5-fluorouracil varied considerably between patients and in the same patient during infusion. Typical data are shown in Fig. 1 , in which one patient (3) showed low levels of drug and wide variation (10-fold) and another patient (25) high levels of drug and little variation (2-fold). Tables I and   25 (Table III) .
720
CLINICAL RESPONSE AND PLASMA LEVELS OF FU (Table III) , the mean C x t value was 24-2 units (mg h FU/ml), the median, 15*9 ui and the mode (Fig. 2) intestinal tract, and is used in combination chemotherapy for this disease. Nevertheless, we do not know the best method and schedule of administration. Some studies indicate that an i.v. loading dose of FU gives the best response (Ansfield et al., 1977) while others suggest that i.v. infusion for 5 days with or without other drugs increases the frequency of response and may increase survival (Grillo-Lopez et at., 1977; Buroker et al., 1977) . Objective responses obtained by the Eastern Cooperative Oncology Group were 6% at a dose of 7-5 mg/kg, 20% at 15 mg/kg and 25% at 20 mg/kg (Horton et al., 1970) . Increasing the dose of FU during a 24h infusion, repeated in 1 or 2 weeks, allows high doses of drug (up to 16 g/24 h infusion) to be given with regression and stasis of large refractory tumours (Spiers et al., 1977) . This dependence of response on dose suggests that response may correlate with the plasma concentration of the drug, in spite of the complex bio-TABLE III.-C x t values of FU (mg/h/ml), patient response and drug toxicity (Vogel et al., 1978) . The enhanced tumour effect reported in animals given this combination ) may result from the high level of FU maintained over a considerable period of time. However, the action of the drug under these conditions may be qualitatively different from that when the drug is given alone (Nayak et al., 1978 is not due to changed plasma concentrations of the latter drug.
Plasma concentrations of FU fluctuated more widely with gravity infusion than with pump infusion, as expected. These concentrations reflect the short half-life (an a, phase of 12 min) of the drug in the plasma (Kirkwood & Frei, 1978 
